Binaytara, shared a post on LinkedIn:
”Immunotherapy works brilliantly in colorectal cancer – for about 5% of patients.
The other 95%? A different story entirely.
In a new expert commentary for The Cancer News, Dr. Ibrahim Halil Sahin breaks down what’s actually driving that resistance, and where the field is now looking for a path forward:
- Why tumor microenvironment matters as much as biomarkers
- How BRAF V600E mutation status and liver metastasis change the calculus
- Why early-stage MSS disease may hold more promise than previously assumed
- What STELLAR-303 and the NICHE trial are revealing about combination strategies
The gap between MSI-H and MSS outcomes isn’t just a biology problem. It’s a research priority.
What’s your experience with biomarker-driven decisions in GI oncology? Drop your thoughts below.
Follow Binaytara for evidence-based oncology insights and expert commentary from leading clinicians.”
Other Articles About Binaytara on OncoDaily.